Search Results - "LEHMANN, Frédéric"

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy by ULLOA-MONTOYA, Fernando, LOUAHED, Jamila, BRICHARD, Vincent G, DIZIER, Benjamin, GRUSELLE, Olivier, SPIESSENS, Bart, LEHMANN, Frédéric F, SUCIU, Stefan, KRUIT, Wim H. J, EGGERMONT, Alexander M. M, VANSTEENKISTE, Johan

“…To detect a pretreatment gene expression signature (GS) predictive of response to MAGE-A3 immunotherapeutic in patients with metastatic melanoma and to…”
Get full text

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results by VANSTEENKISTE, Johan, ZIELINSKI, Marcin, PERDEUS, Jakub, BONNET, Reiner, BASKO, Jazeps, JANILIONIS, Richard, PASSLICK, Bernward, TREASURE, Tom, GILLET, Marc, LEHMANN, Frédéric F, BRICHARD, Vincent G, LINDER, Albert, DAHABREH, Jubrail, GONZALEZ, Emilio E, MALINOWSKI, Wojciech, LOPEZ-BREA, Marta, VANAKESA, Tonu, JASSEM, Jacek, KALOFONOS, Haralabos

“…The MAGE-A3 protein is expressed in approximately 35% of patients with resectable non-small-cell lung cancer (NSCLC). Several immunization approaches against…”
Get full text

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma by KRUIT, Wim H. J, SUCIU, Stefan, BECKER, Juergen C, SPATZ, Alan, EGGERMONT, Alexander M. M, LOUAHED, Jamila, LEHMANN, Frédéric F, BRICHARD, Vincent G, KEILHOLZ, Ulrich, DRENO, Brigitte, MORTIER, Laurent, ROBERT, Caroline, CHIARION-SILENI, Vanna, MAIO, Michele, TESTORI, Alessandro, DORVAL, Thierry, GROB, Jean-Jacques

“…Active immunization against the tumor-specific MAGE-A3 antigen is followed by a few but impressive and durable clinical responses. This randomized phase II…”
Get full text

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma by Baumeister, Susanne H, Murad, Joana, Werner, Lillian, Daley, Heather, Trebeden-Negre, Helene, Gicobi, Joanina K, Schmucker, Adam, Reder, Jake, Sentman, Charles L, Gilham, David E, Lehmann, Frédéric F, Galinsky, Ilene, DiPietro, Heidi, Cummings, Kristen, Munshi, Nikhil C, Stone, Richard M, Neuberg, Donna S, Soiffer, Robert, Dranoff, Glenn, Ritz, Jerome, Nikiforow, Sarah

“…NKG2D ligands are widely expressed in solid and hematologic malignancies but absent or poorly expressed on healthy tissues. We conducted a phase I…”
Get more information

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient by Sallman, David A, Brayer, Jason, Sagatys, Elizabeth M, Lonez, Caroline, Breman, Eytan, Agaugué, Sophie, Verma, Bikash, Gilham, David E, Lehmann, Frédéric F, Davila, Marco L

Get full text

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study by Pujol, Jean-Louis, De Pas, Tommaso, Rittmeyer, Achim, Vallières, Eric, Kubisa, Bartosz, Levchenko, Eugeny, Wiesemann, Sebastian, Masters, Gregory A, Shen, Robert, Tjulandin, Sergei A, Hofmann, Hans-Stefan, Vanhoutte, Nicolas, Salaun, Bruno, Debois, Muriel, Jarnjak, Silvija, De Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent G, Lehmann, Frédéric F

“…Adjuvant platinum-based chemotherapy is standard treatment for surgically resected stage II to IIIA NSCLC, but the relapse rate is high. The preferentially…”
Get more information

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors by Limentani, Steven A., Campone, Mario, Dorval, Thierry, Curigliano, Giuseppe, de Boer, Richard, Vogel, Charles, White, Shane, Bachelot, Thomas, Canon, Jean-Luc, Disis, Mary, Awada, Ahmad, Berlière, Martine, Amant, Frédéric, Levine, Ellis, Burny, Wivine, Callegaro, Andrea, de Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent, Lehmann, Frédéric F.

“…This Phase I dose-escalation study (NCT00058526) assessed the safety and immunogenicity of an anti-cancer immunotherapeutic (recombinant HER2 protein (dHER2)…”
Get full text

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer by Pujol, Jean-Louis, Vansteenkiste, Johan F, De Pas, Tommaso Martino, Atanackovic, Djordje, Reck, Martin, Thomeer, Michiel, Douillard, Jean-Yves, Fasola, Gianpiero, Potter, Vanessa, Taylor, Paul, Bosquée, Lionel, Scheubel, Robert, Jarnjak, Silvija, Debois, Muriel, de Sousa Alves, Pedro, Louahed, Jamila, Brichard, Vincent G, Lehmann, Frédéric F

“…To assess the safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with stage IB-III MAGE-A3-positive non-small-cell lung cancer (NSCLC) who were…”
Get more information

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial by Sallman, David A, Kerre, Tessa, Havelange, Violaine, Poiré, Xavier, Lewalle, Philippe, Wang, Eunice S, Brayer, Jason B, Davila, Marco L, Moors, Ine, Machiels, Jean-Pascal, Awada, Ahmad, Alcantar-Orozco, Erik M, Borissova, Rossitza, Braun, Nathalie, Dheur, Marie-Sophie, Gilham, David E, Lonez, Caroline, Lehmann, Frédéric F, Flament, Anne

“…CYAD-01 is an autologous chimeric antigen receptor (CAR) T-cell product based on the natural killer (NK) group 2D (NKG2D) receptor, which binds eight ligands…”
Get full text

A Factor Graph Approach to Iterative Channel Estimation, Detection, and Decoding for Two-Path Successive Relay Networks by Lehmann, Frederic

“…We consider cooperative communications between a source node and a destination node with the help of two relays. In order to overcome the half-duplex…”
Get full text

407 A phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients by Flament, Anne, Lehmann, Frédéric, Alcantar-Orozco, Erik, Cerf, Emilie, Lonez, Caroline, Gilham, David, Morris, Charles

“…BackgroundThe peptide-based allogeneic chimeric antigen receptor (CAR) T-cell treatment CYAD-101 utilizes an NKG2D receptor that targets eight ligands…”
Get full text

A New Hybrid Message Passing Algorithm for Joint User Activity Detection, Channel Estimation and Data Decoding in Grant-Free OFDM-IDMA by Sagheer, Fakher, Lehmann, Frederic, Berthet, Antoine O.

“…Grant-free access has the potential to reduce considerably the latency with respect to conventional contention-based access. However, in highly dynamic…”
Get full text

Wirtinger Calculus-Based Expectation Propagation in Latent Variable Models Applied to Grant-Free NOMA by Sagheer, Fakher, Lehmann, Frederic, Berthet, Antoine O.

“…Grant-free non-orthogonal multiple access is an emerging communication paradigm, where devices transmit to an access point without explicit permission…”
Get full text

Recursive Bayesian Filtering for Multitarget Track-Before-Detect in Passive Radars by Lehmann, F.

“…This paper presents a Bayesian algorithm for joint detection and tracking in a multitarget setting. Raw measurements are processed using the…”
Get full text

A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer by Curigliano, Giuseppe, Romieu, Gilles, Campone, Mario, Dorval, Thierry, Duck, Lionel, Canon, Jean-Luc, Roemer-Becuwe, Celia, Roselli, Mario, Neciosup, Silvia, Burny, Wivine, Callegaro, Andrea, de Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent, Lehmann, Frédéric F.

“…The objectives of this phase I/II study (NCT00140738) were to evaluate the safety and clinical activity of a cancer immunotherapeutic agent (recombinant HER2…”
Get full text

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies by Springuel, Lorraine, Lonez, Caroline, Alexandre, Bertrand, Van Cutsem, Eric, Machiels, Jean-Pascal H., Van Den Eynde, Marc, Prenen, Hans, Hendlisz, Alain, Shaza, Leila, Carrasco, Javier, Canon, Jean-Luc, Opyrchal, Mateusz, Odunsi, Kunle, Rottey, Sylvie, Gilham, David E., Flament, Anne, Lehmann, Frédéric F.

“…Chimeric antigen receptor-T cells (CAR-Ts) are an exciting new cancer treatment modality exemplified by the recent regulatory approval of two CD19-targeted…”
Get full text

IL-2 Production by Virus- and Tumor-Specific Human CD8 T Cells Is Determined by Their Fine Specificity by Mallard, Eric, Vernel-Pauillac, Frederique, Velu, Thierry, Lehmann, Frederic, Abastado, Jean-Pierre, Salcedo, Margarita, Bercovici, Nadege

“…Memory CD8 T cells mediate rapid and effective immune responses against previously encountered Ags. However, these cells display considerable phenotypic and…”
Get full text

Expression of tumor-associated antigens in breast cancer subtypes by Curigliano, Giuseppe, Bagnardi, Vincenzo, Ghioni, Mariacristina, Louahed, Jamila, Brichard, Vincent, Lehmann, Frederic F., Marra, Antonio, Trapani, Dario, Criscitiello, Carmen, Viale, Giuseppe

“…Tumor-associated antigens (TAAs) are frequently overexpressed in several cancer types. The aim of this study was to investigate the expression of TAAs in…”
Get full text

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types by Lonez, Caroline, Verma, Bikash, Hendlisz, Alain, Aftimos, Philippe, Awada, Ahmad, Van Den Neste, Eric, Catala, Gaetan, Machiels, Jean-Pascal H, Piette, Fanny, Brayer, Jason B, Sallman, David A, Kerre, Tessa, Odunsi, Kunle, Davila, Marco L, Gilham, David E, Lehmann, Frédéric F

“…IntroductionNKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D…”
Get full text

The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients by Thongprasert, Sumitra, Yang, Pan-Chyr, MD, PhD, Lee, Jung Shin, Soo, Ross, Gruselle, Olivier, Myo, Aung, Louahed, Jamila, Lehmann, Frédéric F, Brichard, Vincent G, Coche, Thierry

“…Highlights • MAGE-A3 and PRAME tumor antigen co-expressed in 20% of NSCLC tumors of Asian patients. • Higher rates of antigen-positive tumors in squamous cell…”
Get full text